Research
Hormonal
In the obesity cohort, maridebart cafraglutide resulted in a mean percent change in body weight from baseline to week 52 ranging from -12.3% to -16.2%, compared to -2.5% with placebo.
Maridebart cafraglutide may be an effective treatment option for weight loss in individuals with obesity.
StrongSupportsmedium confidence
In the obesity cohort... the mean percent change in body weight from baseline to week 52... ranged from -12.3%... to -16.2%... with placebo.
Why this rating
Based on the phase 2, double-blind, randomized, placebo-controlled trial design.
Source
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial
Ania M. Jastreboff et al. · New England Journal of Medicine · 2025
rct · n=592Cited 55×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →